Feb 13, 2020 / 01:30PM GMT
Operator
Welcome to the Acorda Therapeutics Fourth Quarter 2019 Update. (Operator Instructions)
Please be advised that this call is being taped at the company's request.
I will now introduce your host for today, Tierney Saccavino, Executive Vice President, Corporate Communications at Acorda. Please go ahead.
Tierney Saccavino - Acorda Therapeutics, Inc. - EVP of Corporate Communications
Thanks, Marcelo. Good morning, everyone. Before we begin, let me remind you that this presentation will contain forward-looking statements. Detailed disclosures can be found in our SEC filings, which are public, and we encourage you to refer to those filings.
I'm going to now pass the call over to our CEO, Ron Cohen.
Ron Cohen - Acorda Therapeutics, Inc. - Founder, CEO, President & Director
Thanks, Tierney. Good morning, everyone. Just starting with INBRIJA. As a reminder, INBRIJA is inhaled levodopa. Levodopa is the gold standard therapy for improving symptoms of Parkinson's disease. And INBRIJA is indicated to
Q4 2019 Acorda Therapeutics Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot